Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
18.86
-0.13 (-0.68%)
Aug 10, 2026, 4:00 PM EDT - Market closed
AAPG Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,236 | -395.26 | -932.86 | -887.17 | -836.1 |
Depreciation & Amortization | 86.48 | 93.17 | 93.2 | 62.92 | 28.33 |
Stock-Based Compensation | 20.87 | 20.92 | 31.5 | 22.11 | 46.97 |
Other Adjustments | 98.1 | 58.84 | 91.23 | 43.82 | -33.53 |
Change in Receivables | -169.8 | 62.75 | -91.54 | -0.39 | -53.97 |
Changes in Inventories | -26.2 | 9.57 | -6.72 | -5.52 | -3.93 |
Changes in Accounts Payable | 14.77 | 19.52 | -23.11 | 24.7 | 47.5 |
Changes in Accrued Expenses | 113.81 | 78.51 | 48.57 | 57.45 | 17.87 |
Changes in Unearned Revenue | -36.49 | 4.09 | 82.98 | -24.66 | 227.39 |
Changes in Other Operating Activities | -39.61 | -63.47 | -19.33 | 52.83 | -45.21 |
Operating Cash Flow | -1,174 | -111.36 | -726.08 | -653.92 | -600.83 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -27.57 | -24.29 | -46.11 | -203.29 | -435.42 |
Sale of Property, Plant & Equipment | - | - | 0.01 | 2.35 | 0.34 |
Purchases of Intangible Assets | - | - | -10.74 | -33.68 | -1.21 |
Purchases of Investments | -4 | -16 | - | - | -1,800 |
Proceeds from Sale of Investments | - | - | - | - | 1,790 |
Cash Acquisitions | -43.34 | -9.52 | -20 | -20 | -20 |
Other Investing Activities | -925.14 | -312.23 | 98.75 | -130 | - |
Investing Cash Flow | -1,000 | -362.04 | 21.92 | -384.61 | -466.52 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | 1,241 | 535.92 | 953.5 | 763.62 | 599.74 |
Long-Term Debt Repaid | -923.99 | -672.85 | -956.09 | -54.5 | -51.15 |
Net Long-Term Debt Issued (Repaid) | 316.98 | -136.93 | -2.59 | 709.11 | 548.59 |
Issuance of Common Stock | 2,305 | 533.95 | 470.09 | 0.02 | 1,301 |
Repurchase of Common Stock | -9.04 | - | -5.92 | -26.78 | -25.87 |
Net Common Stock Issued (Repurchased) | 2,296 | 533.95 | 464.17 | -26.76 | 1,275 |
Other Financing Activities | -72.75 | -82.25 | -92.82 | -63.09 | -41.97 |
Financing Cash Flow | 2,540 | 314.77 | 368.75 | 619.27 | 1,781 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -63.24 | 13.68 | 27.81 | 58.01 | -23.28 |
Net Cash Flow | 365.92 | -158.63 | -335.4 | -419.26 | 710.19 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,202 | -135.65 | -772.19 | -857.2 | -1,036 |
Free Cash Flow Growth | - | - | - | - | - |
FCF Margin | -209.31% | -13.83% | -347.86% | -408.75% | -3712.82% |
Free Cash Flow Per Share | -13.50 | -1.80 | -10.94 | -13.00 | -16.28 |
Levered Free Cash Flow | -840.59 | -425.26 | -798.75 | -209.38 | -397.31 |
Unlevered Free Cash Flow | -1,208 | -281.01 | -760.84 | -932.34 | -1,088 |